Daniel Alain, Inc. (“Daniel Alain”) announced today it has acquired a stake in Applied Biology. Applied Biology is a biotechnology company conducting breakthrough scientific research in alopecia and androgen mediated diseases.
According to Daniel Alain’s CEO and President, Daniel Hafid: “as a leader in hair loss solutions from the world’s finest hair pieces to topical products to stop hair shedding, we seek to offer women a 360 solution for hair loss.” Female Pattern Hair Loss (FPHL) affects up to 50% of women by the age of 65. Currently, only one drug, topical minoxidil, is approved by the US FDA for the treatment of FPHL; however, only a minority of patients respond to topical minoxidil for the treatment of FPHL. The acquisition will allow Daniel Alain to develop and launch novel diagnostic tests for FPHL. Among the diagnostic tests in the pipeline are: a test to identify women that are likely to develop hair loss prior to presenting clinical symptoms as well as a diagnostic test to identify non-responders to topical minoxidil.
The company plans to release additional information as it advances its diagnostic testing program.
Source: Biospace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
